<DOC>
	<DOCNO>NCT02855164</DOCNO>
	<brief_summary>The purpose study assess effect different dos LJN452 respect safety , tolerability , marker liver inflammation patient NASH</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study 12 Weeks LJN452 Treatment NASH Patients</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>male/female patient , 18 year old write informed consent presence NASH histological evidence ( liver biopsy ) elevate alanine aminotransferase ( ALT ) OR phenotypic diagnosis base elevated ALT , BMI diagnosis Type 2 diabetes mellitus ( DM ) Liver fat equal high 10 % MRI previous exposure OCA patient take prohibited medication pregnant nursing ( lactate ) woman current history significant alcohol consumption period 3 consecutive month within 1 year prior screen uncontrolled diabetes mellitus presence cirrhosis hepatic decompensation severe liver impairment previous diagnosis form chronic liver disease patient contraindication MRI image</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LJN452</keyword>
	<keyword>non-alcoholic steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>phase 2</keyword>
	<keyword>adaptive design</keyword>
	<keyword>randomize</keyword>
</DOC>